| 翻訳と辞書 |
VIR-576
VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the virus from inserting itself into a host cell's membrane to initiate an infection. This drug is a synthesized variant of a highly specific natural entry inhibitor designated as VIRIP (virus-inhibitory peptide).
The design of VIR-576 was based on VIRIP which in turn was discovered in 2007 by Frank Kirchhoff and coworkers.〔(【引用サイトリンク】 trans_The discovery of an HIV inhibitor in human blood points to a new kind of fusion inhibitor )〕 This product is being developed by VIRO Pharmaceuticals GmbH & Co. KG.
== Origins and development ==
In 2007, a new natural peptide was discovered in the human organism and was called VIRIP. It is generated from alpha-1-antitrypsin, a protease inhibitor that belongs to the serine family, by matrix metalloproteinases. It was shown that it could interact with the HIV-1 and stop the virus multiplication. In spite of interacting in a highly intensity with gp-41,〔 the VIRIP did not prevent the multiplication of the virus. So, it was decided to increase the efficacy of this molecule creating other ones that could be more powerful. Among these 600 created molecules, there was the VIR-576 which was synthesized using the solid-phase peptide synthesis method. Moreover, another molecule was used to protect the amino groups, the fluorenylmethyloxycarbonyl chloride. The next step was the purification before lyophilizing it with mannitol. Other peptides were made such as the VIR-353 or the VIR-449.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「VIR-576」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|